P2 · validate fit
Rivia
Healthcare IT / clinical trial data platform.
Profile
- Sector
- Healthcare IT / clinical trial data platform
- Geography
- Switzerland
- Reported financing
- $15M Series A reported March 2026
Funding raised is not ARR or valuation.
- Funding stage
- Series A
- Public traction evidence
- Unifies clinical-trial data; no verified ARR disclosed
- Revenue disclosure status
- Not publicly verified
- 2026 revenue
- Not publicly verified
- Research priority
- P2 Order of further research; analyst judgment from the research package, not a recommendation.
- Investment readiness
- Investability unconfirmed. Not yet underwritten
- Core diligence concern
- Confirm commercial recurring contracts, validation cycle and biotech budget sensitivity
- Mandate-fit hypothesis (analyst judgment, unverified)
- Sticky regulated enterprise data workflow, Swiss company base
No forecast or underwriting has been built for Rivia: public revenue and valuation data are not in the research package. The Medida forecast and its MOIC/IRR do not apply to Rivia.
Missing information
- ARR and 2026 revenue
- Customer and retention data
- Entry valuation and ownership availability
Sourcing research collection
25-company desk screen. Each source supports only the stated funding, description and traction.
- Independent reporting Independent news report, published 2026-03-18
Scope: Funding, company description, and only the specific traction stated in public_traction_signal.